Ainos, Inc. (AIMD) Stock Score, Valuation & Financial Research
Ainos, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 10/100.
Quick answer for AIMD
Ainos, Inc. currently has a Wall Street Score of 10/100. The stored market price is $1.43. Its financial score is 1/100. Its valuation score is 0/100. The latest WSS change is -0.1 points. These figures are a research snapshot, not a buy or sell recommendation.
What Ainos, Inc. does
Ainos, Inc. operates as a healthcare technology company, specializing in point-of-care diagnostics and the development of safe, novel treatments for various disease indications. Its current portfolio encompasses a COVID-19 antigen rapid test kit, which integrates with a cloud-based test management platform known as the Ainos App, offering both personal and enterprise applications. Other diagnostic developments include a COVID-19 nucleic acid test and point-of-care testing for volatile organic compounds. Furthermore, the company is progressing with Very Low-Dose Oral Interferon Alpha, an oral formulation engineered to leverage the wide therapeutic applications of IFN-a, and is actively developing a Synthetic RNA (sRNA) technology platform in Taiwan. Established in 1984, this San Diego, California-based firm was formerly known as Amarillo Biosciences, Inc. until its rebranding to Ainos, In
AIMD financial snapshot
- Wall Street Score:
- 10/100
- Current price:
- $1.43
- Market capitalization:
- $10.5M
- Revenue:
- $14K
- Net income:
- $-14.5M
- Free cash flow:
- $-4.6M
- Cash:
- $1.4M
- Total debt:
- $13.8M
- EPS:
- -2.52
- Financial score:
- 1/100
- Valuation score:
- 0/100
- Revenue score:
- 1/100
What stands out
- Reported year-over-year revenue growth is -0.9%.
- Free cash flow is $-4.6M, showing cash burn in the current stored period.
- The balance sheet shows $1.4M of cash versus $13.8M of total debt, so leverage deserves attention.
- The latest Wall Street Score change is -0.1 points: AIMD decreased 0.1 points because some fundamentals weakened.
- The current research record carries a corporate distress warning, which should be reviewed alongside the score.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 1/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-08.
How to research AIMD
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.